Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer

被引：0
|
作者：
Sarah E. Burnette
Emily Poehlein
Hui-Jie Lee
Jeremy Force
Kelly Westbrook
Heather N. Moore
机构：
[1] Atrium Health Wake Forest Baptist,Department of Pharmacy
[2] Duke University,Department of Biostatistics and Bioinformatics
[3] Duke University Cancer Institute,Department of Breast Oncology
[4] Duke University Medical Center,Department of Pharmacy
来源：
Breast Cancer Research and Treatment | 2023年 / 197卷
关键词：
Alpelisib; Metastatic breast cancer; Hormone-receptor positive; PIK3CA; Hyperglycemia; Rash;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：369 / 376
页数：7
相关论文
共 50 条
  • [1] Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer
    Burnette, Sarah E.
    Poehlein, Emily
    Lee, Hui-Jie
    Force, Jeremy
    Westbrook, Kelly
    Moore, Heather N.
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 197 (02) : 369 - 376
  • [2] Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
    Andre, Fabrice
    Ciruelos, Eva
    Rubovszky, Gabor
    Campone, Mario
    Loibl, Sibylle
    Rugo, Hope S.
    Iwata, Hiroji
    Conte, Pierfranco
    Mayer, Ingrid A.
    Kaufman, Bella
    Yamashita, Toshinari
    Lu, Yen-Shen
    Inoue, Kenichi
    Takahashi, Masato
    Papai, Zsuzsanna
    Longin, Anne-Sophie
    Mills, David
    Wilke, Celine
    Hirawat, Samit
    Juric, Dejan
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20): : 1929 - 1940
  • [3] Risk factor (RF) identification (ID) and hyperglycemia (HG) prevention with alpelisib (ALP) plus fulvestrant (FLV) in PIK3CA-mutated, hormone-receptor positive (HR plus ), human epidermal growth factor-2 negative (HER2-) advanced breast cancer (ABC)
    Burnette, S.
    Poehlein, E.
    Lee, H-J.
    Force, J.
    Westbrook, K.
    Moore, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S470 - S470
  • [4] An Updated analysis of risk factor identification and Hyperglycemia prevention with alpelisib plus fulvestrant in PIKC3A-mutated, hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer
    Moore, Heather
    Burnette, Sarah
    Poehlein, Emily
    Lee, Hui-Jie
    Westbrook, Kelly
    Bagwell, Thomas
    Novido, Kervin
    Dent, Susan
    CANCER RESEARCH, 2024, 84 (09)
  • [5] The role of ultrasonographic findings for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer
    Li, Shuo
    Zhang, Qi-Li
    Guo, Rui-Jun
    OPEN MEDICINE, 2023, 18 (01):
  • [6] Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer
    Leenhardt, Fanny
    Alexandre, Marie
    Jacot, William
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (06) : 667 - 675
  • [7] Alpelisib plus endocrine therapy in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study
    Chia, Stephen
    Neven, Patrick
    Ciruelos, Eva M.
    Lerebours, Florence
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Prat, Aleix
    Park, Yeon Hee
    Juric, Dejan
    Turner, Nicholas C.
    Chattar, Yogesh
    Patino, Heather
    Akdere, Murat
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
    Roufai, D. Bello
    Goncalves, A.
    Rouge, T. De La Motte
    Akla, S.
    Blonz, C.
    Grenier, J.
    Gligorov, J.
    Saghatchian, M.
    Bailleux, C.
    Simon, H.
    Desmoulins, I
    Tharin, Z.
    Renaud, E.
    Bertho, M.
    Benderra, M-A
    Delaloge, S.
    Robert, L.
    Cottu, P.
    Pierga, J. Y.
    Loirat, D.
    Bertucci, A.
    Renouf, B.
    Bidard, F. C.
    Lerebours, F.
    ONCOGENE, 2023, 42 (23) : 1951 - 1956
  • [9] Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
    D. Bello Roufai
    A. Gonçalves
    T. De La Motte Rouge
    S. Akla
    C. Blonz
    J. Grenier
    J. Gligorov
    M. Saghatchian
    C. Bailleux
    H. Simon
    I. Desmoulins
    Z. Tharin
    E. Renaud
    M. Bertho
    M-A Benderra
    S. Delaloge
    L. Robert
    P. Cottu
    J. Y. Pierga
    D. Loirat
    A. Bertucci
    B. Renouf
    F. C. Bidard
    F. Lerebours
    Oncogene, 2023, 42 : 1951 - 1956
  • [10] Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1
    Andre, F.
    Ciruelos, E. M.
    Juric, D.
    Loibl, S.
    Campone, M.
    Mayer, I. A.
    Rubovszky, G.
    Yamashita, T.
    Kaufman, B.
    Lu, Y-S
    Inoue, K.
    Papai, Z.
    Takahashi, M.
    Ghaznawi, F.
    Mills, D.
    Kaper, M.
    Miller, M.
    Conte, P. F.
    Iwata, H.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2021, 32 (02) : 208 - 217
12345